Last updated: February 20, 2026
What Is NDC 72578-0055?
NDC 72578-0055 refers to Xyrem (sodium oxybate), indicated for the treatment of narcolepsy, specifically excessive daytime sleepiness and cataplexy. It is marketed by Jazz Pharmaceuticals.
Market Size and Demand Drivers
Epidemiology
- Target Population: Narcolepsy affects approximately 1 in 2,000 individuals (source: National Institute of Neurological Disorders and Stroke[1]).
- US Prevalence: Estimated 150,000 - 200,000 patients.
- Diagnosis Rate: About 50% remain undiagnosed due to lack of awareness.
Treatment Landscape
- Current Standard: Xyrem as the first-line medication for cataplexy and EDS.
- Market Share: Proprietary status limits generic competition; patent expiration expected around 2027.
- Reimbursement and Coverage: Insurance coverage is widely available due to FDA approval and inclusion in clinical guidelines.
Growth Catalysts
- Increase in diagnosis rates.
- Expanded insurance reimbursements.
- Development of novel formulations or indications (e.g., reduction of sleep-related breathing disorders).
Competitive Environment
| Competitors |
Drugs |
Market Position |
Approval Year |
Notes |
| Jazz Pharmaceuticals |
Xyrem (sodium oxybate) |
Market leader |
2002 |
Only FDA-approved drug for narcolepsy |
| HLX01 (Sodium oxybate biosimilar) |
Biosimilar products (expected entry post patent expiry) |
Pending approval |
N/A |
Limited to clinical trials now |
| Other treatments |
Modafinil, Armodafinil, Pitolisant, Solriamfetol |
Adjunct or alternative therapies |
Varies |
Competition in managing EDS and cataplexy |
Patent Timeline:
- Original patent: 2002.
- Secondary patents: Extend exclusivity until approximately 2027, after which generic competition is expected.
Price Trends and Projections
Historical Pricing
- Average Wholesale Price (AWP): Approximately $16,000 - $18,000 per month in 2022.
- Net Price: After negotiations, actual sales prices are lower, estimated around $10,000 - $12,000 per month.
- Historical Growth: Slight decline in per-unit pricing due to discounting and insurance negotiations.
Forecasting Price Changes
| Year |
Expected Price Range (per month) |
Key Assumptions |
Notes |
| 2023 |
$11,000 - $12,000 |
Stable demand, no patent challenges yet |
Market remains under patent protection |
| 2024 |
$11,000 - $12,000 |
No new competitors, insurance coverage |
Maintains current pricing levels |
| 2025 |
$10,500 - $11,500 |
Potential write-downs or discounts |
Slight downward pressure expected |
| 2026 |
$9,500 - $11,000 |
Approaching patent expiration, biosimilar entry |
Price discounts likely to increase |
| 2027 |
$6,000 - $8,000 |
Generic competition begins to enter |
Significant price erosion possible |
Factors Influencing Prices
- Patent expiration: Entry of biosimilars or generics will substantially reduce prices.
- Regulatory changes: Interstate price controls or formulary restrictions could lower prices.
- Market penetration: Expansion into new indications could sustain revenues temporarily.
Revenue Projections
- 2022 Revenue: Estimated at approximately $1.4 billion globally.
- 2023-2024: Growth plateau due to market saturation.
- Post-2027: Revenue decline anticipated as generics capture market share.
Key Considerations for Stakeholders
- Investors: Patent expiration risks; valuations dependent on continued demand and exclusivity.
- Manufacturers: Opportunities in biosimilar development.
- Payors: Likely to negotiate significant discounts post-patent expiry.
Summary Assessment
NDC 72578-0055 (Xyrem) maintains high pricing due to its patent protection, therapeutic uniqueness, and limited competition. The market will face erosive pressure beginning around 2027, with prices projected to decrease by 50% or more over the subsequent two years.
Key Takeaways
- Xyrem is the dominant narcolepsy treatment with high current prices and robust demand.
- Patent protection limits generic competition until approximately 2027.
- Prices are projected to decrease significantly post-patent expiration.
- Growth opportunities lie in expanding indications and biosimilar entry.
- Market dynamics remain sensitive to regulatory, patent, and insurance factors.
FAQs
1. When does patent protection for Xyrem expire?
Patent protection is expected to expire around 2027, enabling biosimilar or generic competition.
2. What are the main drivers for price reduction after patent expiry?
Entry of biosimilars or generics, increased insurance negotiations, and market competition will drive prices down.
3. How does the current market demand compare to projected demand post-2027?
Demand is stable domestically with a growing patient population globally; however, revenue will decline as cheaper alternatives enter the market.
4. Are there authorized biosimilars for sodium oxybate?
As of now, biosimilar development is in early stages; none have received approval for sodium oxybate.
5. What regulatory or policy changes could impact prices?
Price controls, formulary restrictions, or accelerated approval pathways for biosimilars could influence pricing and market dynamics.
References
[1] National Institute of Neurological Disorders and Stroke. (2022). Narcolepsy Fact Sheet. https://www.ninds.nih.gov/health-information/disorders/narcolepsy
